Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Brand-name drug

Simlandi price, strengths & recalls

Brand of adalimumab (generic)

Pharmacies pay $499.25 for 1 kit of Simlandi 100 mg/mL, 0.4 mL auto-injector this week, and from $499.25 to $957.30 across its 2 priced strengths and forms. The generic, adalimumab, costs pharmacies from $490.68. Its official label last changed on July 22, 2026.

Brand
Pharmacies pay$499.25for 1 kit of 100 mg/mL, 0.4 mL auto-injectorNo change in 4 weeks
Fair cash price
$584.64
Strengths
2
Makers
1
Updated
Nov 11

Simlandi price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
100 mg/mL, 0.4 mL auto-injector Brand$499.25$499.25 / 1 kitNo change+4.1%
100 mg/mL, 0.4 mL prefilled syringe Brand$478.65$957.30 / 2 kitsNo change

Simlandi vs generic adalimumab

There is no generic version of Simlandi on the market yet.

GenericAdalimumab prices

Supply status: shortages & recalls

No shortage reportedChecked Nov 16, 2026
No ongoing recallsNone on record

What did you pay for simlandi? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedJuly 22, 2026
Version26 of 14
EffectiveOct 31, 2025
Read the label

These highlights do not include all the information needed to use SIMLANDI safely and effectively. See full prescribing information for SIMLANDI.SIMLANDI® (adalimumab-ryvk) injection, for subcutaneous use Initial U.S. Approval: 2024 SIMLANDI (adalimumab-ryvk) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful dif

This drug has a boxed warning

WARNING: SERIOUS INFECTIONS and MALIGNANCY

SERIOUS INFECTIONS

Patients treated with adalimumab products, including SIMLANDI, are at increased risk for developing serious infections that may lead to hospitalization or death

[see Warnings and Precautions (5.1)]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue SIMLANDI if a patient develops a serious infection or sepsis.

Reported infections include:

Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before SIMLANDI use and during therapy. Initiate treatment for latent TB prior to SIMLANDI use.

Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.

Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.

Carefully consider the risks and benefits of treatment with SIMLANDI prior to initiating therapy in patients with chronic or recurrent infection.

Monitor patients closely for the development of signs and symptoms of infection during and after treatment with SIMLANDI, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy

[see Warnings and Precautions (5.1) and Adverse Reactions (6.1)].

MALIGNANCY

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products

[see Warnings and Precautions (5.2)]. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6-MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants

[see Warnings and Precautions (5.2)].

WARNING: SERIOUS INFECTIONS and MALIGNANCY

See full prescribing information for complete boxed warning.

SERIOUS INFECTIONS (5.1,

6.1):

Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens.

Discontinue SIMLANDI if a patient develops a serious infection or sepsis during treatment.

Perform test for latent TB; if positive, start treatment for TB prior to starting SIMLANDI.

Monitor all patients for active TB during treatment, even if initial latent TB test is negative.

MALIGNANCY (5.2):

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products.

Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including adalimumab products.

Recent major changes (as listed on the label)

Indications and Usage, Hidradenitis Suppurativa (1.8) 10/2025

Indications and Usage, Uveitis (1.9) 10/2025

Dosage and Administration, Recommended Dosage in Juvenile Idiopathic Arthritis or Pediatric Uveitis (2.3) 10/2025

Dosage and Administration, Recommended Dosage in Hidradenitis Suppurativa (2.6) 10/2025

Warnings and Precautions, Autoimmunity (5.9) 10/2025

Indications and Usage, Hidradenitis Suppurativa (1.8) 10/2025

Indications and Usage, Uveitis (1.9) 10/2025

Dosage and Administration, Recommended Dosage in Juvenile Idiopathic Arthritis or Pediatric Uveitis (2.3) 10/2025

Dosage and Administration, Recommended Dosage in Hidradenitis Suppurativa (2.7) 10/2025

Warnings and Precautions, Autoimmunity (5.9) 10/2025

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
BLA761299 · Alvotech USA Inc
First approved
February 23, 2024 (2 years ago)
Latest approved change
November 6, 2025
Approved label
PDF, Nov 7, 2025
Generic makers
None on the market

Simlandi questions

How much does simlandi cost without insurance?

Pharmacies pay about $499.25 for 1 kit of simlandi 100 mg/mL, 0.4 mL auto-injector ($499.25 per unit). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $584.64. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is there a generic for Simlandi?

Yes: adalimumab. Pharmacies pay from $490.68 for it. Compare adalimumab prices.

Is simlandi in shortage?

No shortage is reported for simlandi right now. We check the national shortage list every day.

Has simlandi been recalled?

No recalls are on record for simlandi.

When did the simlandi label last change?

The official label was last updated on July 22, 2026 (version 26). See what changed.

Talk about simlandi

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.